Profound Medical Corp. (NASDAQ:PROF) Shares Acquired by Raymond James Trust N.A.

Raymond James Trust N.A. grew its stake in shares of Profound Medical Corp. (NASDAQ:PROF) by 14.3% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 12,000 shares of the company’s stock after purchasing an additional 1,500 shares during the period. Raymond James Trust N.A.’s holdings in Profound Medical were worth $96,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also modified their holdings of PROF. Thompson Davis & CO. Inc. lifted its stake in Profound Medical by 9.0% during the second quarter. Thompson Davis & CO. Inc. now owns 74,800 shares of the company’s stock valued at $628,000 after buying an additional 6,150 shares in the last quarter. Royce & Associates LP raised its holdings in shares of Profound Medical by 0.6% during the third quarter. Royce & Associates LP now owns 569,298 shares of the company’s stock valued at $4,529,000 after acquiring an additional 3,500 shares during the period. Finally, Connor Clark & Lunn Investment Management Ltd. purchased a new stake in shares of Profound Medical in the 3rd quarter valued at approximately $612,000. Institutional investors and hedge funds own 47.86% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, Raymond James upgraded shares of Profound Medical to a “strong-buy” rating in a research report on Saturday, November 9th.

Profound Medical Trading Up 4.0 %

NASDAQ:PROF opened at $8.15 on Friday. The stock’s 50-day moving average is $7.76 and its two-hundred day moving average is $8.46. The company has a debt-to-equity ratio of 0.11, a current ratio of 6.12 and a quick ratio of 5.16. The stock has a market cap of $201.00 million, a PE ratio of -6.08 and a beta of 0.83. Profound Medical Corp. has a fifty-two week low of $7.11 and a fifty-two week high of $11.42.

About Profound Medical

Profound Medical Corp., together with its subsidiaries, operates as a commercial-stage medical device company that develops and markets incision-free therapeutic systems for the image guided ablation of diseased tissue in Canada, Germany, the United States, and Finland. Its lead product TULSA-PRO system combines magnetic resonance imaging(MRI), robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to provide precise, flexible, and durable ablation of a surgeon defined region of prostate and protect the urethra and rectum.